Neratinib maleate

(Nerlynx)

Neratinib maleate

Drug updated on 11/13/2023

Dosage FormTablet (oral: 40 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
  • Indicated in combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

Product Monograph / Prescribing Information

Document TitleYearSource
Nerlynx (neratinib maleate) Prescribing Information2022Puma Biotechnology, Inc., Los Angeles, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines